What the business is, and whether it's a good one at a fair price.
Markets and sells pharmaceutical products in India across three main buckets: General Medicines (brands like Augmentin and Calpol), Vaccines (Shingrix and others), and a growing Specialty/Oncology portfolio (Trelegy, Nucala, Zejula, Jemperli). FY26 standalone revenue stood at ₹3,821.67 crore with net profit of ₹1,035.98 crore, the first time PAT crossed ₹1,000 crore, and EBITDA margin of 34%, up 290 basis points year-on-year. General Medicines, the largest segment, was held flat by supply disruptions from a contract manufacturer fire (around ₹100 crore impact), while Vaccines delivered double-digit growth of around 11-12% in Q4. The innovation/specialty portfolio has scaled to 6% of Q4 sales from 2% a year ago, with a stated target of 10%, and upcoming launches include Blenrep for multiple myeloma (addressing 40,000+ prevalent patients), Bepirovirsen for hepatitis B, and an RSV vaccine. Inputs costs are dominated by employees at 15.9% of revenue and materials at 11.4%, with capex light at 1.4%, suggesting a marketing and distribution-led model rather than large-scale domestic manufacturing.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from GLAXOSMITHKLINE PHARMA LT's filed financials and exchange disclosures
GLAXOSMITHKLINE PHARMA LT is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol GLAXO.
Yes. Over the trailing twelve months GLAXOSMITHKLINE PHARMA LT reported a net profit of ₹1,068 Cr on revenue of ₹3,955 Cr.
Yes. The dividend yield is 1.50% at the current price. It paid out 69% of its profit as dividend in FY26.
Effectively yes. It holds ₹1,102 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, GLAXOSMITHKLINE PHARMA LT ranks 125 of 169 in Pharmaceuticals — cheaper than 26% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session GLAXOSMITHKLINE PHARMA LT moves 0.91% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by GLAXOSMITHKLINE PHARMA LT appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
